Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMayne Pharma Group Ltd

Mayne Pharma Group Ltd

Healthcare Medical Distribution
PortfolioPortfolio WatchlistWatchlist
Company price
3.08 AUD 0.37 ( 13.65%)
Last update at 2026-11-06T05:11:00Z
VOLUME
867061
Market Cap
221.92M
P/E
8.74

Momentum Score

…

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.67
Low
3.08
High
52 Week Price Range
2.04
Low
6.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Mayne Pharma Group Ltd develops, manufactures and commercializes specialty pharmaceutical products, concentrating on complex generics and niche branded medicines across Australia and the United States. Long-term growth may be supported by its pipeline of complex formulations, expansion in the US market and contract manufacturing or licensing opportunities that could generate recurring revenue.
Key investment risks include intense generic pricing pressure and competition, patent and litigation exposure, revenue concentration on a small number of products, regulatory and manufacturing or supply-chain disruptions, and currency volatility.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.71
Dividend Yield
-
Revenue TTM
383.68M
Revenue Per Share
4.80
Gross Profit TTM
248.07M
Debt / Equity
0.11
ROE
8.20%
Net Debt
-39.05M
ROCE
-5.28%
Diluted EPS TTM
0.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 35.76M -83.30M -190.09M -269.70M -217.82M
Minority interest - - - 0.09M 10.61M
Net income 24.47M -93.84M -174.23M 117.25M -263.34M
Selling general administrative - 114.55M 55.53M 37.21M -28.65M
Selling and marketing expenses - 136.85M 130.70M 125.94M 104.60M
Gross profit 192.21M 247.27M 218.53M 85.43M 170.15M
Reconciled depreciation - - 68.46M 65.44M 81.08M
Ebit -34.28M -22.03M -185.38M -163.00M 11.32M
Ebitda 29.40M 42.08M -116.93M -97.56M 92.40M
Depreciation and amortization 63.69M 64.11M 68.46M 65.44M 81.08M
Operating income -34.28M -23.59M -139.06M -183.43M -122.53M
Other operating expenses 417.96M 431.69M 467.56M -249.38M -121.34M
Interest expense 5.30M 5.01M 4.70M 28.39M 32.10M
Tax provision - 6.78M -21.47M 50.43M 56.13M
Interest income - - 7.07M 6.72M 0.46M
Net interest income - - -27.93M -22.13M -31.97M
Extraordinary items - -3.77M -5.61M 437.28M -0.49M
Income tax expense 4.56M 6.78M -21.47M 47.74M 56.13M
Total revenue 383.68M 408.10M 388.15M 185.53M 423.92M
Total operating expenses 226.49M 270.87M 357.59M 252.12M 171.69M
Cost of revenue 191.47M 160.82M 169.62M 100.10M 253.77M
Total other income expense net 70.04M -59.70M -51.02M -89.67M -204.20M
Discontinued operations - - - 434.60M -71.81M
Net income from continuing ops - - -168.62M -317.44M -273.95M
Net income applicable to common shares - -93.84M -174.23M 117.25M -263.34M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 909.45M 1014.61M 1143.23M 1247.35M 1287.93M
Intangible assets 463.05M 542.11M - 617.26M 405.39M
Other current assets 26.11M 37.21M 26.69M 28.17M 37.80M
Total liab 518.50M 644.32M 689.04M 612.99M 730.81M
Total stockholder equity 390.94M 370.28M 454.19M 634.36M 564.77M
Deferred long term liab - - - 2.04M -729.16M
Other current liab 193.03M 192.14M 282.71M 22.85M 138.86M
Common stock 1229.77M 1225.98M 1224.22M 1233.69M 1238.54M
Capital stock - - - 1233.69M 1238.54M
Retained earnings -1016.51M -1040.98M -944.00M -769.77M -822.41M
Other liab - - - 268.96M 114.71M
Good will - - - 0.00M 22.13M
Other assets - - 0.00M 24.98M -606.22M
Cash 82.25M 59.84M 112.39M 92.62M 96.67M
Total current liabilities 259.94M 261.01M 313.94M 310.96M 610.42M
Current deferred revenue - - 6.54M 241.65M 121.14M
Net debt -39.05M -18.57M -73.57M -45.11M 316.99M
Short term debt 41.65M 38.62M 3.82M 14.43M 407.99M
Short long term debt - - - 10.81M 405.37M
Short long term debt total 43.20M 41.27M 38.82M 47.51M 413.67M
Other stockholder equity - - - -463.92M 148.64M
Property plant equipment - - - 51.48M 225.85M
Total current assets 339.48M 352.79M 460.59M 553.63M 511.62M
Net tangible assets - - - 19.14M -591.90M
Short term investments - 40.56M 39.21M 127.53M 127.53M
Net receivables 175.63M 164.62M 207.68M 194.89M 268.24M
Long term debt - - - 28.48M 0.00M
Inventory 55.49M 50.56M 74.63M 82.70M 108.91M
Accounts payable 25.26M 30.25M 20.87M 32.03M 63.57M
Accumulated other comprehensive income 177.68M 185.29M 173.97M 170.44M 148.64M
Non currrent assets other 14.59M 60.84M 583.92M 2.32M 4.45M
Non current assets total 569.97M 661.81M 682.64M 693.73M 776.31M
Capital lease obligations - - - 8.21M 8.30M
Long term debt total - - - 33.08M 5.67M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - 53.45M 473.49M -28.53M
Change to liabilities - - - 45.32M 42.79M
Total cashflows from investing activities 10.00M -68.07M 53.45M 473.49M -28.53M
Net borrowings - - -10.95M -375.56M 37.01M
Total cash from financing activities -3.23M -0.56M -19.85M -431.89M 27.60M
Change to operating activities - - - -6.47M -1.07M
Net income 31.20M -93.84M -168.62M 117.25M -281.29M
Change in cash 20.04M -50.23M 17.45M -4.06M -1.31M
Begin period cash flow 62.21M 110.07M 92.62M 96.67M 97.98M
End period cash flow 82.25M 59.84M 110.07M 92.62M 96.67M
Total cash from operating activities 15.62M 17.47M -15.30M -42.71M -7.21M
Depreciation 63.69M 72.78M 71.62M 70.47M 78.95M
Other cashflows from investing activities -25.73M -55.80M -34.72M 693.07M -0.00M
Dividends paid - - 0.00M -45.29M 45.29M
Change to inventory -4.66M 25.81M 25.59M -12.13M -2.41M
Change to account receivables -2.71M 12.63M 5.92M 118.70M -66.12M
Sale purchase of stock - -0.15M -10.93M -6.22M -6.22M
Other cashflows from financing activities -3.23M 3.44M 2.03M -1.60M 204.12M
Change to netincome - - - -381.16M 200.57M
Capital expenditures 2.94M 12.28M 20.86M 219.59M 11.85M
Change in working capital 12.29M 42.66M -14.59M 106.58M -68.54M
Stock based compensation - 3.96M 4.09M 6.78M 4.58M
Other non cash items -92.81M -8.09M 92.20M -230.43M 195.13M
Free cash flow 12.67M 5.19M -36.16M -262.30M -19.06M

Peer Comparison*

Sector: Healthcare Industry: Medical Distribution

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MYX
Mayne Pharma Group Ltd		 0.37
13.65%		 3.08 8.74 263.16 0.58 0.55 0.47 1.28
SIG
Sigma Healthcare Ltd		 -
-%		 2.82 47.00 32.15 3.00 6.45 3.15 30.00
EBO
Ebos Group Ltd		 -0.11
0.63%		 17.29 15.13 18.08 0.27 1.34 0.39 9.21
PGC
Paragon Care Ltd		 -0.01
3.23%		 0.15 - 5.98 0.07 0.84 0.17 13.27

Profile*

Mayne Pharma Group Ltd

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

1538 Main North Road, Salisbury South, SA, Australia, 5106

61 8 8209 2666

https://www.maynepharma.com

363

Name Title Year Born
Mr. Shawn Patrick O'Brien B.Sc CEO, MD & Director NA
Mr. Aaron Gray Chief Financial Officer NA
Ms. Lisa Pendlebury VP of Investor Relations & Communications 1975
Ms. Kimberly Parker J.D. Exec. VP & Gen. Counsel NA
Mr. Brant Schofield Exec. VP of Corp. Devel. 1966
Dr. Andrew O. Herdman Ph.D. VP of Group HR NA
Mr. Stefan J. Cross Pres of International Operations 1973
Mr. Daniel Moore Exec. VP of Specialty Products & Patient Solutions NA
Mr. Gerard G. Nahum M.D. Chief Medical Officer NA
Mr. Hemanshu N. Pandya Sr. VP & Head of Generic Product Division NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…